Disc Medicine (NASDAQ:IRON) CFO Jean Franchi Sells 4,075 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CFO Jean Franchi sold 4,075 shares of the firm's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $256,154.50. Following the completion of the transaction, the chief financial officer directly owned 78,424 shares in the company, valued at approximately $4,929,732.64. This represents a 4.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Disc Medicine Stock Down 2.2%

Disc Medicine stock traded down $1.39 during trading on Friday, reaching $61.96. 202,534 shares of the company's stock were exchanged, compared to its average volume of 739,927. Disc Medicine, Inc. has a 52-week low of $30.82 and a 52-week high of $99.50. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -11.55 and a beta of 0.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. The company's 50-day moving average is $77.24 and its two-hundred day moving average is $75.12.

Trending Headlines about Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Cantor Fitzgerald starts/maintains a buy on IRON, providing at least one buy-side analyst endorsement that could support the stock if pipeline news turns constructive. Disc Medicine (IRON) Receives a Buy from Cantor Fitzgerald
• Neutral Sentiment: Company says it will pursue standard U.S. approval after the FDA denied a fast‑track designation — this keeps the program alive but typically implies a longer, less certain pathway than a fast review. Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod
• Neutral Sentiment: Reported short‑interest data shows zero shares (and a 0.0 days‑to‑cover) — likely a data/reporting anomaly and not meaningful evidence of reduced shorting pressure. (No article link available.)
• Negative Sentiment: Regulatory setback — multiple news pieces report an FDA Complete Response Letter on the lead bitopertin program and analysts are downgrading prospects for APOLLO; this is the primary near‑term negative catalyst driving reevaluation of the company’s valuation. Disc Medicine: Downgrading As CRL Puts APOLLO Study Into Question Disc Medicine (IRON) Valuation Check After FDA Complete Response Letter On Lead Bitopertin Program
• Negative Sentiment: Shareholder litigation risk — Pomerantz LLP has opened an investigation on behalf of investors, which raises the potential for future lawsuits or disclosures that could pressure the stock. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
• Negative Sentiment: Insider selling — the CFO disclosed multiple recent sales (tens of thousands of dollars) and other insiders (including John Quisel) have sold shares recently; concentrated insider sales can spook investors about near‑term outlook or liquidity needs. SEC Filing - Insider Transactions Disc Medicine Insider Sells $347,678.66 in Stock John Quisel Sells 13,264 Shares of Disc Medicine
• Negative Sentiment: Analyst cuts and price‑target reductions — HC Wainwright lowered multi‑quarter and multi‑year EPS forecasts and Wells Fargo trimmed its price target (and BMO lowered expectations), increasing downward pressure on the stock’s consensus outlook. MarketBeat IRON - analyst note summary BMO Lowers Expectations for Disc Medicine Wells Fargo Lowers Disc Medicine Price Target

Institutional Trading of Disc Medicine

---

---

Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its stake in Disc Medicine by 110.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company's stock valued at $125,557,000 after acquiring an additional 828,248 shares during the last quarter. BVF Inc. IL bought a new position in shares of Disc Medicine during the fourth quarter worth about $51,616,000. Jennison Associates LLC acquired a new position in Disc Medicine in the fourth quarter worth about $42,252,000. Perceptive Advisors LLC bought a new stake in Disc Medicine in the fourth quarter valued at about $35,794,000. Finally, RA Capital Management L.P. increased its holdings in Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company's stock valued at $156,925,000 after buying an additional 399,026 shares during the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on IRON. TD Cowen reissued a "buy" rating on shares of Disc Medicine in a research report on Friday, December 19th. Wells Fargo & Company reduced their target price on shares of Disc Medicine from $109.00 to $78.00 and set an "overweight" rating on the stock in a research report on Tuesday. Cantor Fitzgerald decreased their target price on shares of Disc Medicine from $153.00 to $125.00 and set an "overweight" rating for the company in a research note on Tuesday. Raymond James Financial reaffirmed a "market perform" rating on shares of Disc Medicine in a research note on Thursday, January 15th. Finally, BMO Capital Markets cut their price objective on shares of Disc Medicine from $120.00 to $100.00 and set an "outperform" rating on the stock in a report on Tuesday. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $104.82.

Read Our Latest Research Report on IRON

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

Read More

• Five stocks we like better than Disc Medicine
• From Quiet Compounder to 2026 Breakout? BSEM
• Have $500? Invest in Elon’s AI Masterplan
• Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
• Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
• Whitney’s Big Tech Play for 2026

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].